Northern Financial Advisors Inc Has $524,000 Position in Danaher Co. (NYSE:DHR)

Northern Financial Advisors Inc lowered its stake in shares of Danaher Co. (NYSE:DHR) by 46.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 2,263 shares of the conglomerate’s stock after selling 1,988 shares during the period. Northern Financial Advisors Inc’s holdings in Danaher were worth $524,000 as of its most recent filing with the SEC.

Other hedge funds have also recently added to or reduced their stakes in the company. BKM Wealth Management LLC acquired a new stake in shares of Danaher during the fourth quarter worth approximately $27,000. Wetzel Investment Advisors Inc. acquired a new stake in shares of Danaher during the fourth quarter worth approximately $29,000. OFI Invest Asset Management acquired a new stake in shares of Danaher during the third quarter worth approximately $30,000. Rakuten Securities Inc. acquired a new stake in shares of Danaher during the fourth quarter worth approximately $36,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Danaher during the fourth quarter worth approximately $41,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Trading Down 0.0 %

DHR stock traded down $0.06 during midday trading on Wednesday, reaching $248.70. The company’s stock had a trading volume of 520,477 shares, compared to its average volume of 2,719,431. The business’s 50-day simple moving average is $248.27 and its 200-day simple moving average is $233.19. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. The stock has a market cap of $184.21 billion, a PE ratio of 42.18, a price-to-earnings-growth ratio of 3.82 and a beta of 0.83. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $259.00.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter last year, the firm posted $2.36 EPS. The company’s quarterly revenue was down 2.6% on a year-over-year basis. As a group, sell-side analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is presently 18.31%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Bank of America raised their price objective on shares of Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Barclays increased their price target on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 24th. Robert W. Baird increased their price target on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Raymond James increased their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and increased their price target for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Insider Activity

In other news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Rainer Blair sold 47,175 shares of the business’s stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The disclosure for this sale can be found here. Insiders sold a total of 103,984 shares of company stock valued at $25,997,094 in the last quarter. Company insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.